TickerFacts.

Company research / NSRX

Nasus Pharma Ltd (NSRX)

Build a valuation ↗↓ Download CSV

CIK 0002029039 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

Figures out of scale. In this company's filings, reported revenue for the year ended 2025-12-31 is more than 100 times total assets. That usually means a value was tagged in the wrong unit. Figures are shown as filed; growth rates are not computed, and the company is left out of screens and comparisons.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-10-08

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-31
Revenue$1.24Bn/an/a
R&D Expense$2.24M$335.0K$567.0K
Operating Income-$4.90M-$1.08M-$1.15M
Net Income-$5.86M-$1.53M-$1.05M
EPS (Diluted)-$0.72-$0.22-$0.20
Total Assets$5.00M$717.0Kn/a
Total Liabilities$2.24M$3.93Mn/a
Shareholders' Equity$2.77M-$3.21M-$3.80M
Cash & Equivalents$1.24M$284.0K$193.0K
Operating Cash Flow-$4.92M-$665.0K-$1.03M
Capital Expenditures$14.0Kn/an/a
Free Cash Flow-$4.93Mn/an/a
Shares Outstanding9.02M7.36Mn/a
Weighted Average Diluted Shares8.01M7.03M7.06M
EPS (Basic)-$0.72-$0.22-$0.15

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView